Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Up 19.8% in December

Janux Therapeutics, Inc. (NASDAQ:JANX) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 7,680,000 shares, a growth of 19.8% from the December 15th total of 6,410,000 shares. Currently, 16.4% of the shares of the company are short sold. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is presently 7.3 days.

Janux Therapeutics Stock Up 0.3 %

Shares of JANX stock traded up $0.11 on Friday, reaching $40.72. 802,219 shares of the stock were exchanged, compared to its average volume of 815,856. The stock has a market cap of $2.14 billion, a P/E ratio of -34.80 and a beta of 3.23. The firm has a 50 day moving average of $53.09 and a two-hundred day moving average of $48.34. Janux Therapeutics has a 1-year low of $7.79 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business’s revenue for the quarter was down 82.6% on a year-over-year basis. On average, equities research analysts predict that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on JANX. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Leerink Partners lifted their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Scotiabank lifted their price objective on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research report on Wednesday, December 4th. Finally, HC Wainwright lifted their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Janux Therapeutics has an average rating of “Buy” and a consensus target price of $89.90.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 13,334 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the sale, the insider now owns 82,139 shares of the company’s stock, valued at $4,507,788.32. The trade was a 13.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David Alan Campbell sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now directly owns 293,054 shares in the company, valued at $17,583,240. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 108,334 shares of company stock valued at $6,070,020. 29.40% of the stock is owned by corporate insiders.

Institutional Trading of Janux Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its position in Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after purchasing an additional 156,675 shares during the period. Ally Bridge Group NY LLC purchased a new stake in Janux Therapeutics during the 3rd quarter worth $4,943,000. Algert Global LLC purchased a new stake in Janux Therapeutics during the 3rd quarter worth $1,112,000. FMR LLC boosted its position in Janux Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares during the period. Finally, Neo Ivy Capital Management purchased a new stake in Janux Therapeutics during the 3rd quarter worth $940,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.